Source: Eur Respir J 2004; 23: 649-650
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Cormican L.J., Schey S., Milburn H.J.. G-CSF enables completion of tuberculosis therapy associated with iatrogenic neutropenia. Eur Respir J 2004; 23: 649-650

Member's Comments

No comment yet.

Related content which might interest you: High serum granulocyte-colony stimulating factor characterises neutrophilic COPD exacerbations associated with dysbiosis Source: ERJ Open Res, 7 (3) 00836-2020; 10.1183/23120541.00836-2020 Year: 2021 Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Febrile episodes without leukopenia are more important for survival than febrile leukopenia in lung cancer patients receiving chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 76s Year: 2005 Glucocorticosteroid therapy as predisposing factor for pulmonary sarcoidosis relapse Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Granulocyte-macrophage colony stimulating factor inhalation therapy as a treatment for pulmonary alveolar proteinosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 A case with rifampicin induced severe trombocytopenia during tuberculosis treatment Source: Annual Congress 2007 - Difficult tuberculosis cases I Year: 2007 Efficacy of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) in a Japanese female patient with pulmonary alveolar proteinosis (PAP) Source: Eur Respir J 2001; 18: Suppl. 33, 221s Year: 2001 Granulocyte colony-stimulating factor enhances the anticancer effects of cisplatin against lung cancer by promoting angiogenesis Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Inhaled granulocyte–macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis Source: Eur Respir J, 51 (4) 1702127; 10.1183/13993003.02127-2017 Year: 2018 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 Antibiotic prophylaxis in chemotherapy-induced neutropenia in lung cancer patients Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Dexamethasone treatment does not inhibit fibroproliferation in chronic lung disease of prematurity Source: Eur Respir J 2003; 21: 842-847 Year: 2003